EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
A phase 1/2 trial of therascreen companion diagnostic kits, Fludarabine, Cyclophosphamide in head and neck squamous cell carcinoma, run by Beijing Biotech, now recruiting.
Overview
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC is a phase 1/2 interventional study registered as NCT07617805 by Beijing Biotech, with 42 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide. Conditions listed: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Shares Fludarabine, Cyclophosphamide.
- TrialDual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Shares Fludarabine, Cyclophosphamide.